Ozanimod vs SULFASALAZINE

Compare Ozanimod (Zeposia) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

Ozanimod

Zeposia · S1P Receptor Modulator

How it works

S1P receptor 1,5 modulator that reduces circulating lymphocytes by retaining them in lymph nodes.

Approved for

Relapsing MS

Ulcerative Colitis

FDA: 2020OralTablet

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

OzanimodSULFASALAZINE

Drug Class

S1P Receptor Modulator

Aminosalicylate (IBD)

Route

Oral

Half-Life

—

FDA Approved

2020

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Ozanimod

Fatigue

>10%

Drug Not Working

>10%

Headache

>10%

Dizziness

1-10%

Nausea

1-10%

Diarrhea

1-10%

Back Pain

0.1-1%

Falls

0.1-1%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

Ozanimod

No specific warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for Ozanimod vs SULFASALAZINE.

Ozanimod vs SULFASALAZINE: What You Should Know

Key Differences

Ozanimod is a S1P Receptor Modulator, while SULFASALAZINE belongs to the Aminosalicylate (IBD) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Safety Considerations

SULFASALAZINE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BALSALAZIDE DISODIUM vs SULFASALAZINE→MESALAMINE vs SULFASALAZINE→ADALIMUMAB vs SULFASALAZINE→SULFASALAZINE vs USTEKINUMAB→AZATHIOPRINE vs SULFASALAZINE→METHOTREXATE vs SULFASALAZINE→

Loading comparison data...

Ozanimod vs SULFASALAZINE

Compare Ozanimod (Zeposia) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

Ozanimod

Zeposia · S1P Receptor Modulator

How it works

S1P receptor 1,5 modulator that reduces circulating lymphocytes by retaining them in lymph nodes.

Approved for

Relapsing MS

Ulcerative Colitis

FDA: 2020OralTablet

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

OzanimodSULFASALAZINE

Drug Class

S1P Receptor Modulator

Aminosalicylate (IBD)

Route

Oral

Half-Life

—

FDA Approved

2020

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Ozanimod

Fatigue

>10%

Drug Not Working

>10%

Headache

>10%

Dizziness

1-10%

Nausea

1-10%

Diarrhea

1-10%

Back Pain

0.1-1%

Falls

0.1-1%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

Ozanimod

No specific warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for Ozanimod vs SULFASALAZINE.

Ozanimod vs SULFASALAZINE: What You Should Know

Key Differences

Safety Considerations

SULFASALAZINE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.